Axon Enterprise, Inc (NASDAQ:AXON) Receives $712.75 Consensus PT from Analysts

Axon Enterprise, Inc (NASDAQ:AXON) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $712.75.

AXON has been the topic of several analyst reports. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd.

Axon Enterprise Stock Down 2.2%

Shares of NASDAQ:AXON opened at $389.84 on Friday. The firm’s 50 day moving average price is $419.15 and its 200 day moving average price is $503.93. The stock has a market cap of $31.42 billion, a price-to-earnings ratio of 156.56, a price-to-earnings-growth ratio of 7.24 and a beta of 1.44. Axon Enterprise has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s revenue was up 33.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.47 earnings per share. As a group, equities research analysts predict that Axon Enterprise will post 1.82 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Erika Nardini sold 198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total transaction of $100,302.84. Following the sale, the director owned 1,946 shares of the company’s stock, valued at approximately $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeri Williams sold 157 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the sale, the director directly owned 1,159 shares in the company, valued at approximately $567,910. The trade was a 11.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 13,855 shares of company stock valued at $7,109,828 in the last quarter. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arkadios Wealth Advisors raised its holdings in Axon Enterprise by 3.5% during the first quarter. Arkadios Wealth Advisors now owns 3,792 shares of the biotechnology company’s stock worth $1,610,000 after purchasing an additional 127 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Axon Enterprise by 10.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,736 shares of the biotechnology company’s stock worth $737,000 after purchasing an additional 162 shares in the last quarter. Empowered Funds LLC raised its holdings in Axon Enterprise by 90.1% during the first quarter. Empowered Funds LLC now owns 6,320 shares of the biotechnology company’s stock worth $2,684,000 after purchasing an additional 2,996 shares in the last quarter. Evelyn Partners Investment Management LLP raised its holdings in Axon Enterprise by 42.6% during the first quarter. Evelyn Partners Investment Management LLP now owns 1,550 shares of the biotechnology company’s stock worth $658,000 after purchasing an additional 463 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Axon Enterprise by 18.6% in the 1st quarter. Evelyn Partners Investment Management Services Ltd now owns 862 shares of the biotechnology company’s stock valued at $366,000 after acquiring an additional 135 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Zacks Research upgraded Axon Enterprise from “hold” to “strong-buy,” signaling improved analyst confidence in the stock’s outlook. Zacks.com
• Positive Sentiment: Coverage highlighted strong momentum in Axon’s Connected Devices business, with demand for TASERs, body cameras, and counter-drone products supporting revenue growth and suggesting the core business remains healthy. Zacks article
• Positive Sentiment: Axon said its AI video tools helped HoneyBaked generate eight-figure operational gains, reinforcing the company’s push to expand its software and AI platform beyond hardware. Seeking Alpha article
• Neutral Sentiment: Several recent articles focused on Axon’s long-term valuation after a sharp pullback, noting that the stock remains down significantly year to date even though the company still has strong longer-term growth credentials. Yahoo Finance article
• Neutral Sentiment: Jim Cramer’s comments that the market may not favor high-multiple stocks like Axon right now are more of a macro/valuation caution than a company-specific negative. Yahoo Finance article
• Neutral Sentiment: Market commentary noted Axon has sometimes lagged peers despite daily gains, indicating the stock is still navigating choppy sentiment rather than reacting to a clear business setback. MarketWatch article

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.